Company intelligence / Profile preview

Nexpep

Melbourne, Victoria, Australiapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

Nexpep was a Melbourne-based biotech company that developed a peptide-based immunotherapy, Nexvax2®, designed to desensitize the immune system’s response to gluten in people with celiac disease. The company’s technology identified toxic gluten peptides responsible for triggering the autoimmune reaction and aimed to reprogram pathogenic T cells. Its lead candidate reached Phase 1 clinical trials before the company’s assets were acquired by ImmusanT, which continued development of both therapeutic and diagnostic products targeting celiac disease.

Therapeutic areas: Gastroenterology
Modalities: Peptide-based immunotherapy
Industry: Biotech

Drug pipeline

2 assets

ERY1-OVA

Pre-clinical

Indications: Proof of concept for immunotolerance

1 more asset in the full pipeline.

Request access →

Partnerships

Inova Diagnostics – commercial agreement for improved serology diagnostic screening tests for celiac disease.

Beyond the preview

Go deeper on Nexpep.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nexpep.

Explore the full profile